Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.62 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28338184 | 0.79 | CHRNA7 (0.50) | CHRNA7CHRNB2CHRNA4SLC18A3MEN1 | |
| SCHEMBL5238467 | 0.79 | CHRNA7 (0.50) | CHRNA7CHRNB2CHRNA4SLC18A3SMN1; SMN2 | |
| SCHEMBL195154 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL29376765 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL195155 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL29615758 | 0.76 | CHRNA7 (0.97) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3223024 | 0.74 | CHRNA7 (0.49) | CHRNA7CHRNB2CHRNA4SIGMAR1SMN1; SMN2 | |
| SCHEMBL8596429 | 0.74 | CYP11B2 (0.49) | CHRNA7CHRNB2CHRNA4CYP2D6CYP1A2 | |
| SCHEMBL4785907 | 0.73 | CHRNA7 (0.88) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL9287736 | 0.72 | CHRNB2 (0.44) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098312-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | Targacept ,Inc (US) | 2011-04-28 | — | — | US | disclosed |
| EP-1315493-A4 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | UNIV GEORGETOWN (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1315493-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002015906-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2002-02-28 | — | — | WO | disclosed |
| US-5494918-A | ANTICHOLESTEROL AGENTS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5385912-A | Hypocholesterolemic or hypolipidemic agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1992015579-A1 | MULTICYCLIC TERTIARY AMINE POLYAROMATIC SQUALENE SYNTHETASE INHIBITORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098312-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | CHRNA10, CHRNA5, CHRNB2 | CHRNA7 6/4885CHRNB2 3/4885CHRNA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.